Lamin A/C Antibody

Applications

Reactivity

Human

Overview
Catalog #	bsm-70138M
Product Name	Lamin A/C Antibody
Applications	WB, IHC, ICC
Specificity	Specific for endogenous levels of the ~64 kDa and ~74 kDa lamin A and C proteins.
Reactivity	Human
Specifications
Conjugation	Unconjugated
Host	Mouse
Source	Recombinant full length human lamin C expressed in and purified from E. Coli.
Clonality	Monoclonal
Clone #	4C4
Isotype	IgG1
Concentration	Lot Dependent
Purification	Purified by Protein G.
Storage Buffer	PBS + 10 mM NaN3.
Storage Condition	Recommended that the undiluted antibody be aliquoted into smaller working volumes (10-30 uL/vial depending on usage) upon arrival and stored long term at -20° C or -80° C, while keeping a working aliquot stored at 4° C for short term. Avoid freeze/thaw cycles. Stable for at least 1 year.
Target
Gene ID	4000
Swiss Prot	P02545
Synonyms	70 kDa lamin antibody, Cardiomyopathy dilated 1A (autosomal dominant) antibody, CDCD1 antibody, CDDC antibody, CMD1A antibody, CMT2B1 antibody, EMD2 antibody, FPL antibody, FPLD antibody, FPLD2 antibody, HGPS antibody, IDC antibody, Lamin A antibody, Lamin A/C antibody, Lamin A/C like 1 antibody, Lamin antibody, Lamin C antibody, Lamin-A/C antibody, LDP1 antibody, LFP antibody, LGMD1B antibody, Limb girdle muscular dystrophy 1B (autosomal dominant) antibody, LMN 1 antibody, LMN A antibody, LMN C antibody, LMN1 antibody, LMNA antibody, LMNA_HUMAN antibody, LMNC antibody, LMNL1 antibody, Prelamin A/C antibody, PRO1 antibody, Renal carcinoma antigen NY REN 32 antibody, Renal carcinoma antigen NY-REN-32 antibody, Renal carcinoma antigen NYREN32 antibody
Background	Lamins A and C are nuclear structural proteins that are part of the intermediate filament family and coded for by the same gene (LMNA). Lamins A and C are nearly identical except for their carboxy termini (McKeon et al., 1986). Mutations in the gene encoding lamins A/C have been shown to cause a variety of diseases including autosomal dominant Emery-Dreifuss muscular dystrophy (Bonne et al., 1995), autosomal dominant limbgirdle muscular dystrophy (Muchir et al., 2000) and Charcot-Marie-Tooth disorder type 2 (De Sandre-Giavonnoli et al., 2002).
Application Dilution
WB	1:300-5000
IHC
ICC	1:100-500